Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Enters into an agreement with a ‘leading biopharmaceutical company’ to support the ongoing development of a biosimilar product. Says this revenue-generating collaboration follows an earlier technology partnership between the two companies, utilising Arecor’s proprietary technology platform, Arestat, and formulation expertise.
Chief Executive Officer Sarah Howell says: ‘This collaboration demonstrates the strength of our know-how and expertise and the value that expertise can bring to our partners’ research programmes. We’re delighted to be working again with an existing partner, strengthening a key relationship and building on our track record of partnerships with leading biopharmaceutical and biotechnology companies.’
Current stock price: 221.00 pence, down 3.9% on Wednesday
12-month change: down 32%
Copyright 2023 Alliance News Ltd. All Rights Reserved.